|
Change of Director's Interest Notice - FB
|
29 June 2023 at 12:30pm
|
|
Change of Director's Interest Notice - FB
|
19 June 2023 at 7:35pm
|
|
Change of Director's Interest Notice - BP
|
19 June 2023 at 7:35pm
|
|
Change of Director's Interest Notice - PM
|
19 June 2023 at 7:35pm
|
|
Details of Company Address
|
19 June 2023 at 11:20am
|
|
IONIC Trial Abstract Published at ASCO
|
26 May 2023 at 8:45am
|
|
Study results show new Sofra drug reduces inflammation
|
19 May 2023 at 8:45am
|
|
Innovative Sofra research presented at European event
|
18 May 2023 at 8:40am
|
|
Change of Director's Interest Notice - FB
|
10 May 2023 at 8:45am
|
|
Upcoming Expiry of Listed Options (ASX Code NOXO)
|
8 May 2023 at 9:15am
|
|
Change of Director's Interest Notice - FB
|
4 May 2023 at 5:30pm
|
|
March 2023 Quarterly Activities Report and Appendix 4C
|
24 April 2023 at 9:00am
|
|
Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
6 April 2023 at 8:30am
|
|
Noxopharm Announces Novel mRNA Vaccine Enhancer
|
28 March 2023 at 8:40am
|
|
Appendix 4D and Half Year 2023 Financial Report
|
24 February 2023 at 1:50pm
|
|
Noxopharm to Present Sofra Study at LUPUS 2023 Conference
|
22 February 2023 at 8:35am
|
|
December 2022 Quarterly Activities Report and Appendix 4C
|
27 January 2023 at 8:55am
|
|
DARRT-2 Trial Efficacy Phase to Commence
|
17 January 2023 at 8:55am
|
|
NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
|
16 December 2022 at 8:45am
|
|
Change of Director's Interest Notice - FB
|
15 December 2022 at 4:45pm
|
|
Notification of cessation of securities - NOX
|
15 December 2022 at 4:45pm
|
|
Federal Innovation Connections Grant Awarded
|
6 December 2022 at 9:20am
|
|
IONIC Trial Progresses as Veyonda Passes Safety Milestone
|
2 December 2022 at 8:45am
|
|
Notification of cessation of securities - NOX
|
21 November 2022 at 5:25pm
|
|
Constitution
|
17 November 2022 at 5:00pm
|
|
Results of Meeting
|
17 November 2022 at 4:59pm
|
|
Noxopharm 2022 AGM Corporate Presentation
|
17 November 2022 at 9:20am
|
|
Noxopharm AGM 2022 Chair's Address
|
17 November 2022 at 9:20am
|
|
CEP-2 Safety Milestone Shows Veyonda Progress
|
16 November 2022 at 8:55am
|
|
Noxopharm Enhances Cash Position via R&D Rebate
|
10 November 2022 at 10:10am
|
|
Change in substantial holding
|
25 October 2022 at 9:20am
|
|
September 2022 Quarterly Activities Report and Appendix 4C
|
21 October 2022 at 8:45am
|
|
2022 AGM Notice of Meeting and Proxy
|
18 October 2022 at 9:25am
|
|
2022 AGM Letter to Shareholders and Proxy
|
18 October 2022 at 9:20am
|
|
Unlisted Options Expiring on 21 November 2022
|
7 October 2022 at 9:55am
|
|
Noxopharm 2022 Annual Report
|
26 September 2022 at 9:20am
|
|
Final Director's Interest Notice - GK
|
20 September 2022 at 6:40pm
|
|
Resignation of Dr Graham Kelly as Non-Executive Director
|
19 September 2022 at 2:15pm
|
|
Novel Dual-cell Therapy Results in Pancreatic Cancer
|
14 September 2022 at 8:30am
|
|
Response to ASX Price Query (Correction to ASX Ticker)
|
2 September 2022 at 10:20am
|
|
Response to ASX Price Query
|
2 September 2022 at 8:55am
|
|
Appendix 4E and Audited Financial Statements
|
25 August 2022 at 4:59pm
|
|
Appendix 4G and Corporate Governance Statement
|
25 August 2022 at 4:50pm
|
|
Noxopharm & UNSW Pancreatic Cancer Research at US Conference
|
16 August 2022 at 8:45am
|
|
CEP-2 Trial Passes Safety Milestone
|
9 August 2022 at 9:15am
|
|
DARRT-2 Trial Safety Milestone and European Site Activated
|
2 August 2022 at 8:45am
|
|
June 2022 Quarterly Activities Report and Appendix 4C
|
27 July 2022 at 9:55am
|
|
Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial
|
5 July 2022 at 9:05am
|
|
$1.45M Grant to Hudson Institute for Noxopharm Collaboration
|
22 June 2022 at 9:55am
|
|
HIMR Collaboration Secures mRNA Vic Acceleration Fund Grant
|
14 June 2022 at 11:35am
|
Noxopharm